Elicera Therapeutics AB Logo

Elicera Therapeutics AB

Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.

ELIC | ST

Overview

Corporate Details

ISIN(s):
SE0015382080 (+1 more)
LEI:
549300I35L0R4INBFG27
Country:
Sweden
Address:
C/O Elicera Therapeutics AB, 402 24 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elicera Therapeutics AB is a clinical-stage immuno-oncology company that develops cell and gene therapies for immune-based cancer treatments. The company's work focuses on two core technology areas: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. Elicera's key asset is the proprietary iTANK (Immuno-Oncology Targeting and Killing) technology platform, a universal solution designed to enhance the efficacy of any CAR T-cell therapy by enabling a multi-targeted immune attack, particularly against solid tumors. The company's pipeline includes four drug candidates, with its oncolytic virus (ELC-100) and CAR T-cell therapy (ELC-301) in or entering clinical phase I/II trials for neuroendocrine tumors and B-cell lymphoma, respectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Margareth Jorvid Other Other 21,700 40,145.00 SEK

Peer Companies

Company Country Ticker View
Dottikon ES Holding AG Logo
Exclusive synthesis of APIs & fine chemicals via hazardous reactions for pharma/biotech industries.
Switzerland DESN
Double Bond Pharmaceutical International AB Logo
Redeveloping drugs with proprietary delivery tech for oncology & infectious diseases.
Sweden DBP B
Develops & commercializes PET/CT tracers for diagnosing cancer & neurological disorders.
South Korea 176750
Dx & Vx Co., Ltd. Logo
Develops innovative diagnostics & vaccines and provides comprehensive life science contract services.
South Korea 180400
Manufactures vet pharma for livestock/aquaculture & distributes premium pet food.
South Korea 044960
ECO ANIMAL HEALTH GROUP PLC Logo
Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.
United Kingdom EAH
Ectin Research AB Logo
Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.
Sweden ECTIN B
Eevia Health Plc Logo
Manufactures validated polyphenol extracts from Arctic plants for the supplement & food industries.
Finland EEVIA
Egetis Therapeutics Logo
Develops and commercializes drugs for serious rare diseases with unmet medical needs.
Sweden EGTX
EIKEN CHEMICAL CO.,LTD. Logo
Manufacturer of clinical diagnostics, specializing in FIT systems for cancer and microbiological tests.
Japan 4549

Talk to a Data Expert

Have a question? We'll get back to you promptly.